In the article on RAV12 antibody, oncosis, and antitumor activity in the March 2007 (1) issue, some of the data in part E of Fig. 5 appeared incorrectly. The corrected Fig. 5 appears below.
Loo D, Pryer N, Young P, Liang T, Coberly S, King KL, Kang K, Roberts P, Tsao M, Xu X, Potts B, Mather JP. The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo.
Mol Cancer Ther
American Association for Cancer Research